Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides

Anti-Cancer Drug Design

Volumn 12, Issue 5, 1997, Pages 395-408

  Henry, Scott P ^a   Monteith, David ^a   Levin, Arthur A ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; INTERCELLULAR ADHESION MOLECULE 1; ISIS 3521; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE INHIBITOR; RAF PROTEIN; UNCLASSIFIED DRUG;

BLOOD CHEMISTRY; BLOOD CLOTTING TIME; CANCER; COMPLEMENT ACTIVATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; HEMATOLOGY; HUMAN; IMMUNOSTIMULATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN NUCLEIC ACID INTERACTION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; THIONUCLEOTIDES;

EID: 0030860587     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. AGRAWAL, S., TEMSAMANI, J. GALBRAITH, W. & TANG, J. (1995). Pharmacokinetics of antisense oligonucleotides. Drug Disposition, 28, 7.
2. ALTMANN, K -H DEAN, NM., FABBRO, D., FREIER, S.M., GEIGER, T., HANER, R , HUSKEN, D., MARTIN, P., MONIA, B.P, MULLER, M., NATT, F, NICKLIN, P., PHILLIPS, J., PIELES, U., SASMOR, H. & MOSER, H.E. (1996). Second generation of antisense oligonucleotides: from nuclease resistance to biological efficant in animals. Chimia, 50, 168.
3. BALLOW, M. & COCHRAN, C.G. (1969). Two anticomplement factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. Journal of Immunology, 103, 944.
4. BOCK, L.C., GRIFFIN, L.C., LATHAM, J.A., VERMASS, E.H. & TOOLE, J.J. (1992). Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature, 355, 564.
5. BRANDA, R.F., MOORE, A.L., MATHEWS, L , MCCORMACK, J.J. & ZON, G. (1993). Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochemical Pharmacology, 45, 2037.
6. BROWN, D A., KANG, S.-H., GRYAZNOV, S.M., DEDIONISIO, L., HEIDENREICH, O, SULLIVAN, S., XU, X. & NERENBERG, M.I. (1994). Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. Journal of Biological Chemistry, 269, 26801.
7. CAMPBELL, J.M., BACON, T.A. & WICKSTROM, E. (1990). Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. Journal of Biochemical and Biophysical Methods, 20, 259.
8. CROOKE, S.T. & BENNETT, C.F. (1996). Progress in antisense oligonucleotide therapeutics. Annual Review of Pharmacology and Toxicology, 36, 107.
9. CROOKE, R M., CROOKE, S.T., GRAHAM, M.J. & COOKE, M.E. (1996). Effect of antisense oligonucleotides on cytokine release from human keratinocytes in an in vitro model of skin. Toxicology and Applied Pharmacology, 140, 85.
10. DEAN, N.M. & MCKAY, R. (1994). Inhibition of protein kinase C-a expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proceedings of the National Academy of Sciences of the USA, 91, 11762.
11. DEAN, N.M , MCKAY, R., MIRAGLIA, L., HOWARD, R., COOPER, S., GIDDINGS, J., NICKLIN, P., MEISTER, L., ZIEL, R., GEIGER, T., MULLER, M. & FABBRO, D. (1996). Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Research, 56, 3499.
12. FURIE. B. (1988). The molecular basis of blood coagulation. Cell, 53, 505.
13. GALBRAITH, W.M., HOBSON, W.C , GICLAS, P.C., SCHECHTER, P.J. & AGRAWAL, S (1994). Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Research Development, 4, 201.
14. GARDNER, W.D , WHITE, P.J. & HOCH, S.O. (1980). Identification of a major human serum DNA-protein as b1h of the alternative pathway of complement activation. Biochemical and Biophysical Research Communications, 94, 61.
15. GEARY, R.S., LEEDS, J.M., HENRY, S.P , MONTEITH, D., TRUONG, L., FITCHETT, J., BURCKIN, T. & LEVIN, A.A. (1996). Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Design, 12, 383.
16. HENRY, S.P., LARKIN, R., NOVOTNY, W.F. & KORNBRUST, D.J. (1994). Effects of ISIS 2302, a phosphorothioate oligonucleotide, on in vitro and in vivo coagulation parameters. Pharmaceutical Research, 11, S-353.
17. HENRY, S.P., BOLTE, H AULETTA, C. & KORNBRUST, D J. (1996a). Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology, in press.
18. HENRY, S.P., TAYLOR, J., MIDGLEY, L., LEVIN, A.A. & KORNBRUST, D.L. (1996b). Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide, following repeated intravenous administration, in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Development, in press.
19. HENRY, S.P., GICLAS, P.C., LEEDS, J , PANGBURN, M., AULETTA, C., LEVIN, A.A. & KORNBRUST, D.J. (1997). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. Journal of Pharmacology and Experimental Therapeutics, 281, 810.
20. HOKE, G. D., DRAPER, K., FREIER, S.M., GONZALEZ, C , DRIVER, V.B , ZOUNES, M.C. & ECKER, D.J. (1991). Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Research, 19, 5743.
21. HUGLI, T E. & MULLER-EBERHARD, H.J. (1978). Anaphylatoxins: C3a and C5a. Advances in Immunology, 26, 1.
22. KAJITA, T. & HUGLI, T.E (1990). C5a-induced neutrophilia: a primary humoral mechanism for recruitment of neutrophils. American Journal of Pathology, 137, 467.
23. KLINMAN, D.M., KYUNG, Y., BEAUCAGE, S.L., CONOVER, J. & KRIEG, A.M. (1996). CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proceedings of the National Academy of Sciences, 93, 2879.
24. KRIEG, A.M., YI, A.-K., MATSON, S., WALDSCHMIDT, T J., BISHOP, G. A., TEASDALE, R., KORETZKY, G. A. & KLINMAN, D.M. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 374, 546.
25. KRIEG, A.M., MATSON, S. & FISHER, E. (1996). Oligonucleotide modification determine the magnitude of B-cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Development, 6, 133.
26. MCINTYRE, K.W., LOMBARD-GILLOOLY, K , PEREZ, J.R., KUNSCH, C., SARMIENTO, U.M., LARIGAN, J.D., LANDRETH, K.T. & NARAYANAN, R (1993). A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kb p65 causes sequence-specific immune stimulation. Antisense Research and Development, 3, 309.
27. MONIA, B P., JOHNSTON, J.F., ECKER, D.J., ZOUNES, M., LIMA, W.F, & FREIER, S.M. (1992). Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. Journal of Biological Chemistry, 267, 19954.
28. MONTEITH, D.K., HENRY, S.P., HOWARD, R.B., FLOURNOY, S., LEVIN, A A., BENNETT, C F. & CROOKE, S T. (1997). Immune stimulation - a class effect of phosphorothioate oligonucleotides in rodents. Anticancer Drug Design, 12, 421.
29. OBERBAUER, R., SCHREINER, G. F. & MEYER, T.W. (1995). Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney International, 48, 1226.
30. PANGBURN, M K. & MULLER-EBERHARD, H.J (1984). The alternative pathway of complement. Springer Seminars in Immunopathology, 7, 163.
31. PISETSKY, D.S. & REICH, C.F (1994). Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Science, 54, 101.
32. RAPPAPORT, J., HANSS, B., KOPP, J.B., COPELEND, T.D., BRUGGEMAN, L.A., COFFMAN, T.M. & KLOTMAN, P.E. (1995). Transport of phosphorothioate oligonucleotide in kidney: implications for molecular therapy. Kidney International, 47, 1462.
33. SARMIENTO, U.M., PEREZ, J.R., BECKER, J.M. & NARAYANAN, R. (1994). In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Research and Development, 4, 99.
34. SCHREIBER, R.D., PANGBURN, M.K., LESAVRE, P.H. & MULLER-EBERHARD, H. J. (1978). Initiation of the alternative pathway of complement: Recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proceedings of the National Academy of Sciences, 75, 3948.
35. SRINIVASAN, S.K., TEWARY, H. K. AND IVERSEN, P.L. (1995). Characterization of binding sites, extent of binding and drug interactions of oligonucleotides with albumin. Antisense Research and Development, 5, 131.
36. WALLACE, T.L., BAZEMORE, S A , KORNBRUST, D.J & COSSUM, P.A. (1996). Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys. 1. Journal of Pharmacology and Experimental Therapeutics, 278, 1306.
37. WU, Q., TSIANG, M & SADLER, J.E. (1992). Localization of the single-stranded DNA binding site in the thrombin anion-binding exosite. Journal of Biological Chemistry, 264, 24408.